305 related articles for article (PubMed ID: 27208830)
1. Pathways to precision medicine in smoking cessation treatments.
Chen LS; Horton A; Bierut L
Neurosci Lett; 2018 Mar; 669():83-92. PubMed ID: 27208830
[TBL] [Abstract][Full Text] [Related]
2. Genomics and personalized medicine:
Chen LS; Bierut LJ
J Food Drug Anal; 2013 Dec; 21(4):S87-S90. PubMed ID: 25214750
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism.
Perez-Paramo YX; Lazarus P
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):333-349. PubMed ID: 33322962
[No Abstract] [Full Text] [Related]
4. Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.
Allenby CE; Boylan KA; Lerman C; Falcone M
J Neuroimmune Pharmacol; 2016 Sep; 11(3):471-83. PubMed ID: 26872457
[TBL] [Abstract][Full Text] [Related]
5. Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women.
Tomaz PRX; Santos JR; Scholz J; Abe TO; Gaya PV; Negrão AB; Krieger JE; Pereira AC; Santos PCJL
BMC Med Genet; 2018 Apr; 19(1):55. PubMed ID: 29621993
[TBL] [Abstract][Full Text] [Related]
6. The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings.
Saccone NL; Baurley JW; Bergen AW; David SP; Elliott HR; Foreman MG; Kaprio J; Piasecki TM; Relton CL; Zawertailo L; Bierut LJ; Tyndale RF; Chen LS;
Nicotine Tob Res; 2018 Mar; 20(4):403-413. PubMed ID: 28472521
[TBL] [Abstract][Full Text] [Related]
7. Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases.
Quaak M; van Schayck CP; Knaapen AM; van Schooten FJ
Mutat Res; 2009 Jul; 667(1-2):44-57. PubMed ID: 19028511
[TBL] [Abstract][Full Text] [Related]
8. From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.
Salloum NC; Buchalter ELF; Chanani S; Espejo G; Ismail MS; Laine RO; Nageeb M; Srivastava AB; Trapp N; Trillo L; Vance E; Wenzinger M; Hartz SM; David SP; Chen LS
Pharmacogenomics; 2018 Jul; 19(10):861-871. PubMed ID: 29914292
[TBL] [Abstract][Full Text] [Related]
9. A glimpse into the future - Personalized medicine for smoking cessation.
Bierut LJ; Johnson EO; Saccone NL
Neuropharmacology; 2014 Jan; 76 Pt B(0 0):592-9. PubMed ID: 24055496
[TBL] [Abstract][Full Text] [Related]
10. Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How.
Chen LS; Zawertailo L; Piasecki TM; Kaprio J; Foreman M; Elliott HR; David SP; Bergen AW; Baurley JW; Tyndale RF; Baker TB; Bierut LJ; Saccone NL;
Nicotine Tob Res; 2018 Mar; 20(4):414-424. PubMed ID: 28498934
[TBL] [Abstract][Full Text] [Related]
11. Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT.
Wells QS; Freiberg MS; Greevy RA; Tyndale RF; Kundu S; Duncan MS; King S; Abney L; Scoville E; Beaulieu DB; Gatskie V; Tindle HA
Nicotine Tob Res; 2018 Nov; 20(12):1489-1496. PubMed ID: 29059367
[TBL] [Abstract][Full Text] [Related]
12. Genetics and smoking cessation improving outcomes in smokers at risk.
Lerman CE; Schnoll RA; Munafò MR
Am J Prev Med; 2007 Dec; 33(6 Suppl):S398-405. PubMed ID: 18021915
[TBL] [Abstract][Full Text] [Related]
13. Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence?
Panagiotou OA; Schuit E; Munafò MR; Bennett DA; Bergen AW; David SP
Nicotine Tob Res; 2019 Aug; 21(9):1289-1293. PubMed ID: 30690475
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.
Schuit E; Panagiotou OA; Munafò MR; Bennett DA; Bergen AW; David SP
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011823. PubMed ID: 28884473
[TBL] [Abstract][Full Text] [Related]
15. Physician barriers to incorporating pharmacogenetic treatment strategies for nicotine dependence into clinical practice.
Schnoll RA; Shields AE
Clin Pharmacol Ther; 2011 Mar; 89(3):345-7. PubMed ID: 21326262
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.
Pintarelli G; Galvan A; Pozzi P; Noci S; Pasetti G; Sala F; Pastorino U; Boffi R; Colombo F
Sci Rep; 2017 Dec; 7(1):16730. PubMed ID: 29196725
[TBL] [Abstract][Full Text] [Related]
17. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.
Chen LS; Baker TB; Piper ME; Breslau N; Cannon DS; Doheny KF; Gogarten SM; Johnson EO; Saccone NL; Wang JC; Weiss RB; Goate AM; Bierut LJ
Am J Psychiatry; 2012 Jul; 169(7):735-42. PubMed ID: 22648373
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of nicotine addiction: role of dopamine.
Herman AI; DeVito EE; Jensen KP; Sofuoglu M
Pharmacogenomics; 2014 Feb; 15(2):221-34. PubMed ID: 24444411
[TBL] [Abstract][Full Text] [Related]
19. The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions.
Siegel SD; Lerman C; Flitter A; Schnoll RA
Cancer Prev Res (Phila); 2020 Mar; 13(3):261-272. PubMed ID: 32132120
[TBL] [Abstract][Full Text] [Related]
20. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy.
Sarginson JE; Killen JD; Lazzeroni LC; Fortmann SP; Ryan HS; Schatzberg AF; Murphy GM
Am J Med Genet B Neuropsychiatr Genet; 2011 Apr; 156B(3):275-84. PubMed ID: 21268243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
